Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Apr;9(4):2154-2156.
doi: 10.21037/tcr.2020.03.07.

Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment

Shibani Mukherjee  1 , Aroumougame Asaithamby  1
Affiliations
Editorial

Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment

Shibani Mukherjee et al. Transl Cancer Res. 2020 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2020.03.07). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Schematics show the overall outcome of the randomized clinical trial with Placebo and Olaparib reported in Golan et al. (2019).
See this image and copyright information in PMC

Comment on

  • Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Golan T, et al. N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157963 Free PMC article. Clinical Trial.

References

    1. Ferrone CR, Levine DA, Tang LH, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 2009;27:433-8. 10.1200/JCO.2008.18.5546 - DOI - PMC - PubMed
    1. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005;42:711-9. 10.1136/jmg.2004.028829 - DOI - PMC - PubMed
    1. Pilarski R. The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families. Am Soc Clin Oncol Educ Book 2019;39:79-86. 10.1200/EDBK_238977 - DOI - PubMed
    1. Kim R, Byer J, Saif MW. BRCA and pancreatic cancer: selection of chemotherapy. JOP 2012;13:180-1. - PubMed
    1. Malyuchenko NV, Kotova EY, Kulaeva OI, et al. PARP1 Inhibitors: antitumor drug design. Acta Naturae 2015;7:27-37. 10.32607/20758251-2015-7-3-27-37 - DOI - PMC - PubMed